Eliquis ICD-10 Coding Guide The Complete 2026 Reference

There is no Eliquis ICD-10 Coding Guide for Eliquis itself ICD-10-CM code diagnoses, not drug names. Instead, coders assign Z79.01 (long-term current use of anticoagulants) alongside the diagnosis that put the patient on it, such as atrial fibrillation or a history of DVT. Getting the sequencing and the surrounding codes right is where most of the actual work happens. 

Is there a specific ICD-10 code for Eliquis?

No. Eliquis (apixaban) has no drug-specific ICD-10-CM code, because the classification system codes conditions, not prescriptions. What you’re really coding is why the patient takes it, plus a status code confirming they’re on it long-term. That status code is Z79.01, and it applies whether the drug in the chart is Eliquis, Xarelto, Pradaxa, Coumadin, Lovenox, or heparin ICD-10-CM treats the whole anticoagulant class the same way.

(For another diagnosis-code deep dive, see our Anemia ICD-10 Codes guide or our E11.42 Diagnosis Code breakdown.)

Z79.01 what it covers and when it applies

Z79.01 sits in category Z79 (long-term current drug therapy), under the broader chapter for factors influencing health status (Z77-Z99). It’s billable, and it’s valid for the current ICD-10-CM fiscal year (October 1, 2025 through September 30, 2026).

The ICD-10-CM Official Guidelines address this category in Section I.C.21.c.3: a Z79 code applies whenever a patient is on medication for an extended period preventing a clot, managing a chronic condition, or treating a disease over months or years. There’s no fixed day-count that triggers it. A patient started on Eliquis three days ago for a new DVT, with refills authorized, qualifies the same as someone who’s been on it for a decade, as long as the therapy is expected to continue.

What Z79.01 does not cover: short courses of medication for acute problems (a week of antibiotics doesn’t count), and it isn’t used for detoxification or withdrawal-management therapy.

Why Eliquis patients carry this code

Apixaban is a factor Xa inhibitor developed by Bristol-Myers Squibb and Pfizer. The FDA approved it in December 2012 to reduce stroke and systemic embolism risk in patients with nonvalvular atrial fibrillation, still the most common reason it shows up in outpatient charts. A 2014 supplemental approval added DVT prophylaxis after hip or knee replacement surgery, based on the ADVANCE trial program. Eliquis is also indicated for treating an active DVT or PE and for reducing recurrence risk afterward.

The clinical case for choosing apixaban over warfarin largely traces back to the ARISTOTLE trial a randomized comparison in over 18,000 atrial fibrillation patients, published in the New England Journal of Medicine in 2011, which found apixaban reduced stroke/systemic embolism and major bleeding compared with warfarin. That’s a big part of why Z79.01 now appears far more often on AFib charts than the catch-all Z79.899.

Each indication pairs with a different underlying code:

• AFib maintenance → a code from category I48, plus Z79.01
• Active DVT/PE treatment → the active thrombosis code, plus Z79.01, shifting to a personal-history code once the acute episode resolves
• Post-surgical prophylaxis → the aftercare/joint-replacement code for the encounter, with Z79.01 underneath it

Z79.01 vs. Z79.02 vs. Z79.82

These three get mixed up constantly, because all three cover “blood thinners” in casual conversation  but ICD-10-CM splits them by mechanism, not by how a clinician talks about them.

Code	Covers	Typical drugs
Z79.01	Long-term use of anticoagulants	Eliquis (apixaban), Xarelto (rivaroxaban), Pradaxa (dabigatran), Coumadin (warfarin), Lovenox (enoxaparin), heparin
Z79.02	Long-term use of antithrombotics/antiplatelets	Plavix (clopidogrel), Brilinta (ticagrelor), Effient (prasugrel)
Z79.82	Long-term use of aspirin	Aspirin, including low-dose cardioprotective aspirin

Anticoagulants block the clotting cascade directly; antiplatelets stop platelets from clumping a different mechanism, which is why ICD-10-CM gives them separate codes rather than treating one as a subtype of the other. A patient on Eliquis and daily low-dose aspirin (common after certain cardiac procedures) should have both Z79.01 and Z79.82 on the claim not one or the other.

Coding the condition behind the prescription

Atrial fibrillation subtypes

Category I48 breaks AFib down further than many charts document, a common gap for practices running cardiology medical billing:

• I48.0  paroxysmal
• I48.11  longstanding persistent
• I48.19  other persistent
• I48.20 chronic
• I48.21  permanent
• I48.91  unspecified

Payers increasingly expect the specific subtype when the documentation supports it. Defaulting to I48.91 out of habit, when the chart actually says “permanent” or “longstanding persistent,” leaves accuracy on the table and can draw audit attention.

DVT, PE, and a retired code you need to stop using

If you’re still coding Z86.71 for personal history of venous thrombosis and embolism, that code has been retired; it’s now a non-billable category header. You need one of the two codes underneath it:

• Z86.711  personal history of pulmonary embolism
• Z86.718  personal history of other venous thrombosis and embolism (this is the one for DVT history)

Practices whose superbills or EHR templates haven’t been updated since this split are still generating claims with the invalid parent code  and those come back rejected. During active DVT/PE treatment, use the active thrombosis code (from category I82 for DVT, I26 for PE) alongside Z79.01. Once the acute episode resolves and Eliquis continues purely for prevention, switch to the personal-history code.

Sequencing  which code goes first?

This is where the actual coding judgment lives, and it depends entirely on why the patient is being seen today:

• Visit is about the condition itself (e.g., an AFib follow-up) → the condition code (I48.x) leads, Z79.01 is secondary
• Visit exists specifically to monitor the drug (e.g., an INR check, or periodic renal function labs for a patient on Eliquis) → Z51.81 (encounter for therapeutic drug level monitoring) leads, Z79.01 is secondary

Can Z79.01 be a primary diagnosis?

Yes  but only when the entire reason for the encounter is managing the anticoagulant itself, not the underlying disease. It’s not on the short list of Z codes required to always be listed first, and it’s not barred from that position either. What it can’t do is substitute for the condition code: a note that reads “seen for AFib follow-up, continue Eliquis” still needs the AFib code first. A note that reads “here for anticoagulation follow-up, no other complaints” supports Z51.81 first with Z79.01 second.

When Eliquis causes bleeding instead of preventing it

Like every anticoagulant, Eliquis carries a bleeding risk, and the code you choose depends entirely on what’s actually documented, not on the fact that bleeding occurred.

• T45.515A  adverse effect of anticoagulants, initial encounter (subsequent encounter: T45.515D; sequela: T45.515S). Use this when a provider documents a reaction to a properly prescribed, correctly administered dose.
• D68.32  hemorrhagic disorder due to extrinsic circulating anticoagulants. This is reserved for a genuine coagulation defect, not simply “patient bled while on Eliquis.”

This distinction has real history behind it. AHA Coding Clinic, First Quarter 2016, directed coders toward D68.32 for anticoagulant-related bleeding, while that year’s AHA ICD-10 Coding Handbook didn’t apply it to comparable scenarios in its own chapter a genuine conflict that AHA corrected in the 2017 edition of the Handbook by adding D68.32 to its practice examples. Coders still debate whether a physician needs to document an actual hemorrhagic disorder versus just a bleeding site plus a drug cause before D68.32 applies. When documentation is ambiguous, query the provider rather than guess.

Separately, the AHA Coding Clinic for ICD-10-CM/PCS, Second Quarter 2022, addressed a related question directly: whether Eliquis should be classified as an anticoagulant or an antithrombotic for coding purposes. The ruling confirmed Eliquis is coded as an anticoagulant meaning Z79.01, not Z79.02, applies to long-term Eliquis use. If your reference library gates this ruling behind a subscription, the practical takeaway is the one line that matters for your claims: Eliquis = Z79.01.

If a patient has a documented allergy to apixaban itself (not an adverse bleeding event), report Z88.8 (allergy status to other drugs, medicaments, and biological substances) ICD-10-CM doesn’t have an anticoagulant-specific allergy status code.

The generic apixaban timeline coders should know

One detail that rarely makes it into coding guides: generic apixaban has technically been FDA-approved since December 2019, when the agency cleared applications from two manufacturers. It still isn’t available in U.S. pharmacies. Patent litigation between the brand holders and generic applicants pushed the earliest commercial launch to April 1, 2028  so for now, Eliquis remains a brand-only prescription in American billing, unlike Xarelto, which got its first generic competitor in March 2025. Nothing about the coding changes once generic apixaban does arrive; Z79.01 covers the drug class, not the brand name.

5 documentation errors that trigger denials

• Listing Z79.01 with no linked diagnosis the payer sees “on an anticoagulant” but never learns why, which reads as unsupported medical necessity. See our CO 16 Denial Code guide for how this specific gap shows up on an EOB.
• Using the retired Z86.71 instead of Z86.711 or Z86.718.
• Applying D68.32 to routine, mild bleeding on a correctly dosed anticoagulant, when documentation doesn’t describe an actual coagulation defect.
• Confusing Z79.01 with Z79.02 is especially common when a patient is on Eliquis plus a separate antiplatelet, and only one code makes the claim. This is also a frequent driver behind a CO 197 denial.
• Defaulting to unspecified AFib (I48.91) when the chart documents a specific subtype.

If a claim is already denied over one of these, it’s worth understanding what your next step actually accomplishes see our guides on what “appeal upheld” really means and what “appeal overturned” means and what happens next.

Conclusion

Accurate ICD-10 coding for patients taking Eliquis depends on documenting the reason for therapy and distinguishing long-term anticoagulant use from complications caused by the medication. In most cases, Z79.01 is appropriate for chronic anticoagulant therapy, while diagnosis codes for the underlying condition and any documented adverse effects should also be reported when applicable. Staying current with ICD-10-CM guidelines and payer policies helps improve claim accuracy, reduce denials, and support compliant medical billing.

If your practice is spending more time chasing denials than seeing patients, our medical coding and billing services and denial management team can help. Browse more coding and billing guides on our blog.

FAQs